Latest News Archive

Please select Category, Year, and then Month to display items

The first clinical PhD in nuclear medicine completed at the UFS

18 April 2024 | Story Andre Damons | Photo Charl Devenish

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans.

News Archive

UFS PhD student receives more than R5,8 million to take agricultural research to African farmers

2015-07-06

Prof Maryke Labuschagne and Bright Peprah. (Photo: Supplied)

Bright Peprah, a Plant Breeding PhD student from Ghana in the Department of Plant Sciences at the University of the Free State received an award from the competitive Program for Emerging Agricultural Research Leaders (PEARL) of the Bill and Melinda Gates Foundation (BMGF) for one of his projects.

From the more than 750 proposals for funding that were received from African researchers, only 19 received funding from PEARL. PEARL is an agricultural initiative by the BMGF to take agricultural research products to African farmers. It also aims at involving the youth and women in agriculture.

Peprah’s proposal to introgress beta carotene into farmer-preferred cassava landraces was part of the final 19 proposals funded. The project is being led by the Council for Scientific and Industrial Research (CSIR)Crops Research Institute (CRI), and has the International Institute of Tropical Agriculture (IITA) and the International Centre for Tropical Agriculture (CIAT) as international partners with Peprah as the principal investigator.

The development of nutrient-dense cassava cultivars needs attention to eliminate the ramifications of malnutrition among the poor in an inexpensive and more sustainable way.
Photo: Supplied

He received $473 000 (R5,8 million) for his project on the improvement of beta-carotene content in cassava.

Peprah decided on this project because the populations of underdeveloped and developing countries, such as Ghana, commonly suffer undernourishment and/or hidden hunger, predisposing them to diseases from micronutrients deficiencies. “Vitamin A deficiency constitutes an endemic public health problem which affects women and children largely,” he says.

“In Africa, cassava is widely consumed by the populace. Unfortunately, in these areas, malnutrition is endemic to a significant extent, partly due to the low micronutrients in this tuberous root crop, which is a major component of most household diets. It is for this reason that the development of nutrient- dense cassava cultivars needs much attention to eliminate the ramifications of malnutrition among the poor in an inexpensive and more sustainable way.

“To date we have selected top eight genotypes from germplasm collected from the International Institute of Tropical Agriculture (IITA) which are high in carotenoids and also poundable, a key trait to Ghanaian farmers. These eight genotypes have been planted at different locations in Ghana, and being evaluated by different stakeholders (consumers, researchers, producers, commercial farmers, processors, etc.). If found suitable, the genotypes will be released to farmers, which we hope will solve some of the micronutrient problems in Ghana.

“My projects seek to develop new cassava varieties that will have both high dry matter and beta carotene which has been reported to be negatively correlated (as one increase, the other decreases). The breeding method will be crossing varieties that are high in beta carotene with those with high dry matter, and checking the performance of the seedlings later. Developing such new varieties (yellow flesh cassava) will increase their adoption rate by Ghanaian farmers,” he said.

Prof Maryke Labuschagne, Professor in Plant Breeding in the Department Plant Sciences and Peprah’s study leader, said: “This project has the potential to alleviate vitamin A deficiency in the West African region, where this deficiency is rampant, causing blindness in many people, especially children."

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept